Related Experiment Video

Updated: Apr 6, 2026

Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery in Clinical Research
08:42

Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery in Clinical Research

Published on: October 22, 2014

28.1K

Elevated Human Endothelial Cell-Specific Molecule-1 Level and Its Association With Coronary Artery Disease in

Chang Xiong1, Zi-wen Zhao, Zhao-yang Chen

  • 1From the Department of Cardiology, Union Hospital, Fujian Medical University; and Fujian Institute of Coronary Artery Disease, Fuzhou, P.R. China.

Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research
|July 23, 2015
PubMed

Insights

Serum endocan levels are linked to coronary artery disease (CAD) in hypertensive patients. Higher endocan may indicate a greater risk of atherosclerosis development.

Area of Science:

  • Cardiovascular Medicine
  • Biomarker Research
  • Endothelial Biology

Background:

  • Endothelial dysfunction is central to coronary artery disease (CAD) pathophysiology.
  • Human endothelial cell-specific molecule-1 (endocan) is a potential marker for endothelial dysfunction.
  • Investigating serum endocan in hypertension patients with CAD is crucial.

Purpose of the Study:

  • To explore the association between serum endocan levels and CAD presence.
  • To evaluate the relationship between serum endocan and CAD severity in hypertensive individuals.

Main Methods:

  • Enzyme-linked immunosorbent assay (ELISA) for serum endocan measurement.
  • Coronary angiography to assess CAD presence and severity.
  • Study included 190 eligible hypertension patients.

Main Results:

  • Hypertensive patients with CAD showed significantly higher serum endocan levels (1.63 ± 0.51 ng/mL) versus controls (1.31 ± 0.65 ng/mL).
  • Serum endocan was an independent predictor of CAD presence (OR, 2.662; P < 0.001).
  • Endocan levels correlated with the SYNergy between PCI with TAXUS and Cardiac Surgery score (r = 0.349, P = 0.001).

Conclusions:

  • Serum endocan is independently associated with CAD presence and severity in hypertension.
  • Elevated serum endocan may signify an increased risk for atherosclerosis development.
Abstract

More Related Videos

Ultrasound Assessment of Endothelial Function: A Technical Guideline of the Flow-mediated Dilation Test06:35

Ultrasound Assessment of Endothelial Function: A Technical Guideline of the Flow-mediated Dilation Test

Published on: April 27, 2016

19.0K
Harvest of Endothelial Cells from the Balloon Tips of Swan-Ganz Catheters after Right Heart Catheterization07:45

Harvest of Endothelial Cells from the Balloon Tips of Swan-Ganz Catheters after Right Heart Catheterization

Published on: January 23, 2019

8.8K

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.7K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
771
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
729
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
994
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
1.5K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
565